Haemonetics (HAE)
(Delayed Data from NYSE)
$93.19 USD
-2.08 (-2.18%)
Updated May 21, 2024 04:00 PM ET
After-Market: $85.00 -8.19 (-8.79%) 7:08 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.19 USD
-2.08 (-2.18%)
Updated May 21, 2024 04:00 PM ET
After-Market: $85.00 -8.19 (-8.79%) 7:08 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
International Business Aids NuVasive, Pricing Woe Remains
by Zacks Equity Research
NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.
5 Top Efficient Stocks to Add to Your Portfolio
by Tirthankar Chakraborty
Companies with favorable efficiency levels are likely to be on investors' radar irrespective of market conditions as price performance is believed to be positively correlated with efficiency
BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
NuVasive's SpineTRACK Registry Gains New CMS Designation
by Zacks Equity Research
NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.
Luminex (LMNX) Banks on Solid Product Line, Competition Rife
by Zacks Equity Research
Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.
Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis
by Zacks Equity Research
Abiomed (ABMD) gets second FDA PMA for its flagship Impella in a row, with a view to treating patients with High Risk PCI.
Haemonetics (HAE) Banks on Plasma Franchise, Competition Rife
by Zacks Equity Research
Haemonetics' (HAE) strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth.
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) gains from promising financial results in the third quarter of fiscal 2018.
Is Surprise Coming for Haemonetics (HAE) This Earnings Season?
by Zacks Equity Research
Is Surprise Coming for Haemonetics (HAE) This Earnings Season?
Haemonetics Banks on Hospital Business, Competition Rife
by Zacks Equity Research
For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.
Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.
Haemonetics (HAE) Grows on Strong Plasma, Competition Rife
by Zacks Equity Research
Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.
Haemonetics (HAE) in Focus: Stock Moves 10% Higher
by Zacks Equity Research
Haemonetics (HAE) saw its shares rise nearly 10% on the day after the company reported better-than-expected second quarter and first Half Fiscal 2018 results.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
by Zacks Equity Research
LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.
Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company
by Zacks Equity Research
Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company
3 Best Stocks with Upgraded Broker Ratings to Invest In Now
by Zacks Equity Research
Selecting stocks from the vast investment universe is not an easy task. In such a situation, sound broker advice helps to pick the right stocks.
Haemonetics Banks on Solid Plasma & Haemonetics Management
by Zacks Equity Research
Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).
Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.
Why Earnings Season Could Be Great for Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Can PerkinElmer (PKI) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat outlook, volatility in the foreign exchange rate is likely to mar PerkinElmer's (PKI) results in the second quarter.
Haemonetics Plasma Arm Advances, Blood Center Sluggish
by Zacks Equity Research
On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).
Haemonetics Rides on Solid Plasma, Slows Blood Center Growth
by Zacks Equity Research
On Jun 13, we issued an updated research report on Haemonetics Corporation (HAE).
Haemonetics (HAE) Down 2.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.